Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OyaGen HER-driven oncology program
- Development stage
- Preclinical
- Lead developer
- OyaGen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OyaGen's HER-driven oncology program is a preclinical-stage effort focused on the development of first-in-class small molecule inhibitors targeting the Human Epidermal Growth Factor Receptor (HER) family. This family of receptor tyrosine kinases includes EGFR (HER1), HER2 (ERBB2), HER3 (ERBB3), and HER4 (ERBB4), which are frequently implicated in the proliferation and survival of various solid tumors. The program aims to address therapeutic resistance encountered with existing HER-targeted agents, such as monoclonal antibodies and earlier-generation tyrosine kinase inhibitors (TKIs), by utilizing a novel binding mechanism or targeting multiple family members simultaneously. The lead compounds are being optimized for the treatment of HER-driven malignancies, including breast, lung, and gastric cancers.
- Other names
- HER-driven oncology programOyaGen HER family programOyaGen HER2 program
02
Targets
ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on OyaGen HER-driven oncology program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OyaGen HER-driven oncology program.